<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330524</url>
  </required_header>
  <id_info>
    <org_study_id>8749</org_study_id>
    <nct_id>NCT01330524</nct_id>
  </id_info>
  <brief_title>Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo</brief_title>
  <official_title>Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic
      Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema
      and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided
      in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected
      trough vitreal and placebo will be injected in control group. BCVA and Visual field will be
      then measured in these two groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Best corrected visual acuity(BCVA)</measure>
    <time_frame>6 month</time_frame>
    <description>outcome method of measurement: Snellen chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Visual Field</measure>
    <time_frame>6 month</time_frame>
    <description>Automated perimeter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Acute Nonarteritic Anterior Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Avastin and Triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin and Triamcinolone</intervention_name>
    <description>1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal</description>
    <arm_group_label>Avastin and Triamcinolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2mg placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Sudden mono ocular vision loss associated with optic disc edema and positive Marcus
             Gunn (&lt;30 days)

        Exclusion criteria:

          -  Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy)

          -  Neurologic defect

          -  Abnormal ESR, CRP, any history of retina or vitreal surgery

          -  Severe corneal opacity which makes retina examination impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Labbafinejad medical center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>morteza entezari, Associate Professor</last_name>
      <phone>00982122585952</phone>
      <email>entmort@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>morteza entezari, associat of profesor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>morteza entezari</name_title>
    <organization>Ophthalmic Research center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

